Our Principal Advisors lend their knowledge, experience and insight to our product development and business and include:
Sir Gregory Winter
CB, FRS, Hon FRCP, Hon FTSE. Special Advisor
Sir Gregory Winter is a pioneer of therapeutic monoclonal antibodies. He invented techniques to both humanise and later to fully-humanise antibodies for therapeutic uses.
Dr Jim Peacock
AC, FAA, FRS, FTSE, FAIAST. Special Advisor
Jim Peacock is the former Chief Scientist of Australia and a past President of the Australian Academy of Science. He was Chief of CSIRO Plant Industry 1978-2003.
Prof. William Rawlinson
AM, MBBS, Ph.D., FRACP, FRCPA. Clinical Advisor
Professor William Rawlinson is Director of the Virology Division, SEALS Microbiology at Prince of Wales Hospital, Sydney.
Christopher M Abbott
Ph.D. (Hon), AM, FCA. Founder and Chairman Emeritus
Christopher Abbott has had an extensive and successful career in investment and venture capital. From 1967 to 1976, he was an Executive Director with the Rothschild-affiliated Merchant Bank in Australia, and from 1976 to 1989 he was an external Director of a number of public companies. During this period he founded Maple-Brown Abbott Limited, an investment firm now managing $10 billion in securities. Mr Abbott also co-founded Peplin Limited (acquired by LEO Pharma A/S in 2009), a biotechnology business focused on inventing innovative dermatology products. Since 1985, he has been an early investor in many Australian biotechnology start-ups.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.